lobbying_activities
Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API
238 rows where filing_period = "third_quarter", filing_year = 2013 and issue_code = "PHA" sorted by filing_year descending
This data as json, CSV (advanced)
Suggested facets: filing_type, is_termination, received_date (date)
| id | filing_uuid | filing_type | registrant_name | registrant_id | client_name | filing_year ▲ | filing_period | issue_code | specific_issues | government_entities | income_amount | expense_amount | is_no_activity | is_termination | received_date |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1437696 | INJURED WORKERS PHARMACY 17cfd669-23d4-4744-8596-a049f67188ed | Q3 | INJURED WORKERS PHARMACY | 400765309 | INJURED WORKERS PHARMACY | 2013 | third_quarter | PHA | Transparency of Pharmacy Benefit Managers (bill sponsored by Rep. McMorris-Rodgers and Senator Mark Pryor); Longshoreman and Harbor Workers Amendment Act of 2011 sponsored by Senator Isakson. | HOUSE OF REPRESENTATIVES,SENATE | 0 | 0 | 2013-10-02T13:48:41.543000-04:00 | ||
| 1437726 | KATE MOSS 85962f96-c422-4123-bbc4-767fb75f1d2b | Q3 | KATE MOSS | 25988 | CVS HEALTH | 2013 | third_quarter | PHA | Issues related to prescription drugabuse and drug supply chain safety. | HOUSE OF REPRESENTATIVES,SENATE | 40000 | 0 | 0 | 2013-10-02T15:28:05.723000-04:00 | |
| 1437742 | MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY 8c49cb63-258a-4a25-ac6a-4546565120ce | Q3 | MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY | 62277 | MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY | 2013 | third_quarter | PHA | HR 1919 Safeguarding America's Pharmaceutical Act of 2013 and the Senate "track and trace" legislation | HOUSE OF REPRESENTATIVES,SENATE | 280000 | 0 | 0 | 2013-10-02T15:50:14.960000-04:00 | |
| 1438047 | DELAHUNT GROUP, LLC 5baf2e6c-9c65-4721-9544-66922753a6fe | Q3 | DELAHUNT GROUP, LLC | 401066001 | HEALIANCE PHARMACEUTICALS | 2013 | third_quarter | PHA | innovative diabetes treatment. | HOUSE OF REPRESENTATIVES,Natl Security Agency (NSA),SENATE,State, Dept of (DOS),Treasury, Dept of | 45000 | 0 | 0 | 2013-10-03T22:23:19.973000-04:00 | |
| 1438058 | AMERICAN COLLEGE OF CLINICAL PHARMACY 6ed427b5-52d2-46cd-89ad-983cceb8d0a0 | Q3 | AMERICAN COLLEGE OF CLINICAL PHARMACY | 57258 | AMERICAN COLLEGE OF CLINICAL PHARMACY | 2013 | third_quarter | PHA | Coverage for direct patient care services of qualified pharmacists under Medicare and other public health programs. | Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,SENATE | 111725 | 0 | 0 | 2013-10-04T09:57:27.077000-04:00 | |
| 1438136 | THORSEN FRENCH ADVOCACY LLC 350e721c-2f4c-4ac4-a912-c2e85544bf31 | Q3 | THORSEN FRENCH ADVOCACY LLC | 400599826 | ASTRAZENECA PHARMACEUTICALS LP | 2013 | third_quarter | PHA | Issues realted to access to pharmaceuticals. | HOUSE OF REPRESENTATIVES,SENATE | 30000 | 0 | 0 | 2013-10-04T13:40:14.003000-04:00 | |
| 1438310 | AMERICAN COLLEGE OF EMERGENCY PHYSICIANS 35cbceef-109d-411e-a006-705685a5d3d6 | Q3 | AMERICAN COLLEGE OF EMERGENCY PHYSICIANS | 1967 | AMERICAN COLLEGE OF EMERGENCY PHYSICIANS | 2013 | third_quarter | PHA | H.R.3089 - Compounding Clarity Act H.R.3204 - Drug Quality & Security Act (Upton/Waxman) S.959 - Pharmaceutical Compounding Quality and Accountability Act S.1323 - Protecting Our Youth from Dangerous Synthetic Drugs Act of 2013 | HOUSE OF REPRESENTATIVES,SENATE | 609420 | 0 | 0 | 2013-10-07T11:17:22.010000-04:00 | |
| 1438332 | CYBER SECURITY RESEARCH CONSULTANTS, LLC d9368a99-7b5a-4814-8ee1-77b80b8ac6fa | Q3 | CYBER SECURITY RESEARCH CONSULTANTS, LLC | 91694 | PDFRAZER CONSULTING INC CANADIAN INTERNATIONAL PHARMACY ASSOCIATION | 2013 | third_quarter | PHA | Monitoring drug importation legislation | HOUSE OF REPRESENTATIVES,SENATE | 20000 | 0 | 0 | 2013-10-07T12:07:29.140000-04:00 | |
| 1438584 | UPS (UNITED PARCEL SERVICE) 12dd094d-6cba-4414-873c-2be7dc2ec610 | Q3 | UPS (UNITED PARCEL SERVICE) | 39223 | UPS (UNITED PARCEL SERVICE) | 2013 | third_quarter | PHA | - HR 1919 / S.959 Healthcare Supply Chain Safety related to Track & Trace legislation - HR 3204 Drug Quality and Security Act regarding track and trace issues | Commerce, Dept of (DOC),Executive Office of the President (EOP),Federal Aviation Administration (FAA),Health & Human Services, Dept of (HHS),Homeland Security, Dept of (DHS),HOUSE OF REPRESENTATIVES,Labor, Dept of (DOL),Office of Management & Budget (OMB),SENATE,State, Dept of (DOS),Transportation, Dept of (DOT),Treasury, Dept of,U.S. Trade Representative (USTR),White House Office | 1411126 | 0 | 0 | 2013-10-07T18:01:27.610000-04:00 | |
| 1438811 | RUBICON ADVISORS, LLC 9e17c0c2-ed8d-40d5-a2ce-2237013e0c1c | Q3 | RUBICON ADVISORS, LLC | 315091 | DYNAVAX TECHNOLOGIES | 2013 | third_quarter | PHA | Food and Drug Administration - Vaccines | Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE | 60000 | 0 | 0 | 2013-10-08T11:48:20.270000-04:00 | |
| 1438815 | RUBICON ADVISORS, LLC d0981dd1-3944-41f4-af52-3f13754b1d88 | Q3 | RUBICON ADVISORS, LLC | 315091 | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2013 | third_quarter | PHA | Physician Payment Sunshine Act S 2029 Patent Settlements H.R. 14328 .316 Affordable Healthcare Choices Act | HOUSE OF REPRESENTATIVES,SENATE | 30000 | 0 | 0 | 2013-10-08T11:50:22.643000-04:00 | |
| 1438900 | CAPITOL HILL CONSULTING GROUP a96ecda9-13f9-4e5d-9dd9-c2dd55a37909 | Q3 | CAPITOL HILL CONSULTING GROUP | 72053 | PROFESSIONAL COMPOUNDING CENTERS OF AMERICA | 2013 | third_quarter | PHA | Pharmaceutical Compounding and Accountability Act (S. 959) The Compounding Clarity Act (HR 3089) The Drug Quality and Security Act (HR 3204) | HOUSE OF REPRESENTATIVES,SENATE | 45000 | 0 | 0 | 2013-10-08T13:52:15.407000-04:00 | |
| 1438942 | CAPITOL HILL CONSULTING GROUP a709a019-0610-480f-867a-c10a346431fc | Q3 | CAPITOL HILL CONSULTING GROUP | 72053 | ROCK & ASSOCIATES | 2013 | third_quarter | PHA | Pharmaceutical Compounding and Accountability Act (S.959) The Compounding Clarity Act (HR 3089) The Drug Quality and Security Act (HR 3204) | HOUSE OF REPRESENTATIVES,SENATE | 15400 | 0 | 0 | 2013-10-08T14:48:33.263000-04:00 | |
| 1438957 | CAPITOL HILL CONSULTING GROUP 3d6fc421-5520-4897-8753-a40ee26ab480 | Q3 | CAPITOL HILL CONSULTING GROUP | 72053 | WELLNESS PHARMACY | 2013 | third_quarter | PHA | Pharmaceutical Compounding and Accountability Act (S.959) The Compounding Clarity Act (HR 3089) The Drug Quality and Security Act (HR 3204) | HOUSE OF REPRESENTATIVES,SENATE | 6750 | 0 | 0 | 2013-10-08T15:03:38.857000-04:00 | |
| 1438960 | ROCK & ASSOCIATES 2401e3b7-3900-4465-8fbe-d8506eacb1e6 | Q3 | ROCK & ASSOCIATES | 33545 | BRAIDWOOD MANAGEMENT, INC. | 2013 | third_quarter | PHA | S.959, H.R. 3089 & H.R. 3204, legislation affecting the operation of compounding pharmacies and the availability of compounded medications. | HOUSE OF REPRESENTATIVES,SENATE | 11200 | 0 | 0 | 2013-10-08T15:05:41.507000-04:00 | |
| 1438984 | RUBICON ADVISORS, LLC b9ef8de1-4b1b-45b6-b86e-0848aae828bf | Q3 | RUBICON ADVISORS, LLC | 315091 | STATE MUTUAL INSURANCE COMPANY | 2013 | third_quarter | PHA | Pharmacy - Compounding | HOUSE OF REPRESENTATIVES,SENATE | 60000 | 0 | 0 | 2013-10-08T15:56:53.730000-04:00 | |
| 1438985 | RUBICON ADVISORS, LLC 13489f11-50fa-4bc0-8b1a-5bc14a78942b | Q3 | RUBICON ADVISORS, LLC | 315091 | TEVA PHARMACEUTICALS USA | 2013 | third_quarter | PHA | Patent Settlements H.R. 1432, Generic Biologies S H.R. 1695, H.R. 5629, Physican Payment Sunshine Act S 2029, Patent Reform H.R. 1908, Import Safety Act H.R. 3100 Affodable Health Choices Act | HOUSE OF REPRESENTATIVES,SENATE | 105000 | 0 | 0 | 2013-10-08T15:57:55.370000-04:00 | |
| 1438999 | ROCK & ASSOCIATES 407d1250-c99d-4a09-9f06-d1b3569776b2 | Q3 | ROCK & ASSOCIATES | 33545 | CAPITOL HILL CONSULTING GROUP (ON BEHALF OF WELLNESS PHARMACY) | 2013 | third_quarter | PHA | S.959, H.R. 3089 & H.R. 3204, legislation affecting the operation of compounding pharmacies and the availability of compounded medications. | HOUSE OF REPRESENTATIVES,SENATE | 0 | 0 | 2013-10-08T16:17:03.940000-04:00 | ||
| 1439020 | ROCK & ASSOCIATES 2efc8e48-038e-47f8-9779-fedb2371ef54 | Q3 | ROCK & ASSOCIATES | 33545 | DIAMONDBACK DRUGS | 2013 | third_quarter | PHA | S.959, H.R. 3089 & H.R. 3204, legislation affecting the operation of compounding pharmacies and the availability of compounded medications. | HOUSE OF REPRESENTATIVES,SENATE | 11200 | 0 | 0 | 2013-10-08T16:25:12.103000-04:00 | |
| 1439035 | ROCK & ASSOCIATES 9128610a-95d7-427a-87ab-8fde1303fb55 | Q3 | ROCK & ASSOCIATES | 33545 | VETERINARY PHARMACIES OF AMERICA, INC. | 2013 | third_quarter | PHA | S.959, H.R. 3089 & H.R. 3204, legislation affecting the operation of compounding pharmacies and the availability of compounded medications. | HOUSE OF REPRESENTATIVES,SENATE | 11200 | 0 | 0 | 2013-10-08T16:37:20.167000-04:00 | |
| 1439051 | ROCK & ASSOCIATES b6a474f2-50c7-40de-b5aa-797e3d39a188 | Q3 | ROCK & ASSOCIATES | 33545 | WEDGEWOOD VILLAGE PHARMACY, INC. | 2013 | third_quarter | PHA | S.959, H.R. 3089 & H.R. 3204, legislation affecting the operation of compounding pharmacies and the availability of compounded medications. | HOUSE OF REPRESENTATIVES,SENATE | 11200 | 0 | 0 | 2013-10-08T16:47:28.187000-04:00 | |
| 1439068 | ROCK & ASSOCIATES 77b91e60-fecc-4557-b3a9-32df69be9c13 | Q3 | ROCK & ASSOCIATES | 33545 | WOMEN'S INTERNATIONAL PHARMACY | 2013 | third_quarter | PHA | S.959, H.R. 3089 & H.R. 3204, legislation affecting the operation of compounding pharmacies and the availability of compounded medications. | HOUSE OF REPRESENTATIVES,SENATE | 11200 | 0 | 0 | 2013-10-08T16:56:37.737000-04:00 | |
| 1439210 | MR. VINCENT A. PANVINI 20e44c9f-e73c-4b0a-81f1-59d0ae032565 | Q3 | MR. VINCENT A. PANVINI | 401008845 | PHRMA | 2013 | third_quarter | PHA | Medicare Part D Rebates TransPacific Partnership | HOUSE OF REPRESENTATIVES,SENATE | 10000 | 0 | 0 | 2013-10-09T10:00:43.087000-04:00 | |
| 1439226 | MR. VINCENT A. PANVINI b2da815a-9fdd-4068-b28a-b9a62d65b389 | Q3 | MR. VINCENT A. PANVINI | 401008845 | ELI LILLY AND COMPANY | 2013 | third_quarter | PHA | TransPacific Partnership Medicare Part D Rebates | HOUSE OF REPRESENTATIVES,SENATE | 0 | 0 | 2013-10-09T10:10:44.683000-04:00 | ||
| 1439544 | HAAKE & ASSOCIATES 165dac66-79a6-4502-8f72-bd5b1ed6d454 | Q3 | HAAKE & ASSOCIATES | 17226 | JOHNSON & JOHNSON SERVICES INC. | 2013 | third_quarter | PHA | Policy and procurement matters related to vaccines | Air Force, Dept of,Army, Dept of (Other),Defense, Dept of (DOD),Navy, Dept of,U.S. Coast Guard (USCG),U.S. Marines | 30000 | 0 | 0 | 2013-10-09T14:25:39.807000-04:00 | |
| 1439563 | MCGUIREWOODS CONSULTING (A SUBSIDIARY OF MCGUIREWOODS LLP) 8a00ac15-4b78-46f5-b5b5-042247a5f1d0 | Q3 | MCGUIREWOODS CONSULTING (A SUBSIDIARY OF MCGUIREWOODS LLP) | 24486 | ASL PHARMACY HOLDING COMPANY, INC. | 2013 | third_quarter | PHA | Track compounding legislation; S.959 | HOUSE OF REPRESENTATIVES,SENATE | 25000 | 0 | 0 | 2013-10-09T14:39:48.570000-04:00 | |
| 1439571 | MCGUIREWOODS CONSULTING (A SUBSIDIARY OF MCGUIREWOODS LLP) 98d696b9-4b3f-49a1-bc2a-646ded22692e | Q3 | MCGUIREWOODS CONSULTING (A SUBSIDIARY OF MCGUIREWOODS LLP) | 24486 | ALLIED MEDICAL SUPPLY, INC. | 2013 | third_quarter | PHA | Issues affecting resellers of pharmaceutical products in HR 1919 and S. 957 | HOUSE OF REPRESENTATIVES,SENATE | 50000 | 0 | 0 | 2013-10-09T14:41:53.490000-04:00 | |
| 1439576 | MCGUIREWOODS CONSULTING (A SUBSIDIARY OF MCGUIREWOODS LLP) de27842e-7a5f-48e5-af2a-7d42c610f65e | Q3 | MCGUIREWOODS CONSULTING (A SUBSIDIARY OF MCGUIREWOODS LLP) | 24486 | DIAMONDBACK DRUGS OF DELAWARE, LLC | 2013 | third_quarter | PHA | Track compounding legislation, S.959 | HOUSE OF REPRESENTATIVES,SENATE | 50000 | 0 | 0 | 2013-10-09T14:43:56.520000-04:00 | |
| 1439633 | MCDERMOTT WILL & SCHULTE LLP 5ecc2361-5e02-48f3-987b-db56f256cb07 | Q3 | MCDERMOTT WILL & SCHULTE LLP | 24338 | ALLERGAN, INC. | 2013 | third_quarter | PHA | Issues related to Section 340B of the Public Health Service Act; FDA issues; health reform implementation | Executive Office of the President (EOP),HOUSE OF REPRESENTATIVES,SENATE | 20000 | 0 | 0 | 2013-10-09T15:13:28.940000-04:00 | |
| 1440059 | PD FRAZER CONSULTING, INC. b6ca348f-0c8b-44ab-8f53-cb3beebd6237 | Q3 | PD FRAZER CONSULTING, INC. | 65998 | CANADA INTERNATIONAL PHARMACY ASSOCIATION | 2013 | third_quarter | PHA | Monitor the development of proposed bills about the importation of prescription drugs. | HOUSE OF REPRESENTATIVES,SENATE | 40000 | 0 | 0 | 2013-10-10T11:35:10.250000-04:00 | |
| 1440189 | RUBICON ADVISORS, LLC 2e648f86-3ade-46de-91bb-f1ed35c672ee | Q3 | RUBICON ADVISORS, LLC | 315091 | ALLIANCE TO PREVENT THE ABUSE OF MEDICINES | 2013 | third_quarter | PHA | Prescription Drug Abuse Police | HOUSE OF REPRESENTATIVES,SENATE | 52500 | 0 | 0 | 2013-10-10T14:02:22.970000-04:00 | |
| 1440204 | NATIONAL COMMUNITY PHARMACISTS ASSOCIATION 4b652acc-f909-4fd3-a612-657a49b74835 | Q3 | NATIONAL COMMUNITY PHARMACISTS ASSOCIATION | 27478 | NATIONAL COMMUNITY PHARMACISTS ASSOCIATION | 2013 | third_quarter | PHA | S. 959, Pharmaceutical Compounding Quality and Accountability Act; S. 957- Drug Supply Chain Security Act; H.R. 1919- Safeguarding America's Pharmaceuticals Act of 2013; H.R. 3089- Compounding Clarity Act of 2013; H.R. 3204 - Drug Quality and Security Act; S.867- The Medicare Prescription Drug Program Integrity and Transparency Act of 2013 | Agency for Healthcare Research & Quality (AHRQ),Centers For Medicare and Medicaid Services (CMS),Defense, Dept of (DOD),Drug Enforcement Administration (DEA),Food & Drug Administration (FDA),Government Accountability Office (GAO),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Office of Management & Budget (OMB),Office of Personnel Management (OPM),SENATE | 205000 | 0 | 0 | 2013-10-10T14:11:31.693000-04:00 | |
| 1440213 | SMITH GARSON FKA SMITH DAWSON & ANDREWS 12ab312d-b9a3-43f1-bdc5-4d4ea9f7e883 | 3A | SMITH GARSON FKA SMITH DAWSON & ANDREWS | 35707 | CURE PHARMACEUTICALS | 2013 | third_quarter | PHA | Discussed federal government unpaid invoice from 2011 & 2012. | Defense, Dept of (DOD),HOUSE OF REPRESENTATIVES,SENATE | 0 | 0 | 2013-10-10T14:15:39.453000-04:00 | ||
| 1440602 | LNE GROUP d1f205c0-a221-4dff-993c-424c18d99fcf | Q3 | LNE GROUP | 308811 | INTRINSIQ MATERIALS | 2013 | third_quarter | PHA | Lobbied on pharmacy issues | HOUSE OF REPRESENTATIVES,SENATE | 10000 | 0 | 0 | 2013-10-11T09:52:23.303000-04:00 | |
| 1440688 | ACADEMY OF MANAGED CARE PHARMACY 2388cc5c-6ce0-41ef-8c38-c752b9165c66 | Q3 | ACADEMY OF MANAGED CARE PHARMACY | 48793 | ACADEMY OF MANAGED CARE PHARMACY | 2013 | third_quarter | PHA | S 959 - legislation would define a compounding manufacturer and a traditional compounder and provide limitations on each entity's ability to compound drugs -- HR 2186 requires registration of manufacturers that compound and requires Secretary to develop list of drugs that cannot be compounded, generally does not apply to a licensed pharmacist compounding in a state licensed pharmacy -- S 957 legislation establishes uniform national policy for the drug supply chain -- HR 1919 legislation provides enhanced securityin the drug distribution chain | HOUSE OF REPRESENTATIVES,SENATE | 200000 | 0 | 0 | 2013-10-11T10:55:03.973000-04:00 | |
| 1440735 | INDEPENDENT PHARMACY COOPERATIVE d4bdcaa6-9c00-46a0-ae12-88e0ad9a67de | Q3 | INDEPENDENT PHARMACY COOPERATIVE | 313098 | INDEPENDENT PHARMACY COOPERATIVE | 2013 | third_quarter | PHA | H.R. 3204 Drug Quality and Security Act (Support) | HOUSE OF REPRESENTATIVES,SENATE | 0 | 0 | 2013-10-11T11:15:22.110000-04:00 | ||
| 1440896 | STANTON PARK GROUP f8d30612-a0f7-43ef-998a-4c4cfbd192aa | Q3 | STANTON PARK GROUP | 83717 | ALKERMES, INC. | 2013 | third_quarter | PHA | increasing acceptance of medication assisted therapy in treating abuse of alcohol and opioid dependence | HOUSE OF REPRESENTATIVES,SENATE | 30000 | 0 | 0 | 2013-10-11T12:46:37.847000-04:00 | |
| 1441243 | PARRY, ROMANI, DECONCINI & SYMMS 4d154815-348f-456c-991d-9c4f5102473a | Q3 | PARRY, ROMANI, DECONCINI & SYMMS | 30792 | POZEN, INC. | 2013 | third_quarter | PHA | Support H.R. 2985 - The Combination Drug Development Incentive Act of 2013, to provide incentives for new drug development. | HOUSE OF REPRESENTATIVES,SENATE | 36000 | 0 | 0 | 2013-10-11T16:13:50.853000-04:00 | |
| 1441432 | GENENTECH, INC d7be651d-323c-426d-aa92-f5e578580365 | Q3 | GENENTECH, INC | 15920 | GENENTECH INC | 2013 | third_quarter | PHA | Monitor Drug Safety and pedigree legislation. Monitor legislation and oversight on compounding pharmacies. | HOUSE OF REPRESENTATIVES,SENATE | 890000 | 0 | 0 | 2013-10-11T22:03:33.380000-04:00 | |
| 1441929 | GREATER NEW YORK HOSPITAL ASSOCIATION b2e141c3-6151-4a71-af7c-982a6398edd8 | Q3 | GREATER NEW YORK HOSPITAL ASSOCIATION | 16830 | GREATER NEW YORK HOSPITAL ASSOCIATION | 2013 | third_quarter | PHA | Reducing the costs of pharmaceuticals, medical devices, and supplies for consumers and health care providers, including drug shortage legislation, implementation of P.L. 112-144, medical device pricing and tax issues (including gag clauses), and preserving access to group purchasing organizations (GPOs); drug compounding bills (S.959, H.R.2090, H.R.3204); 340b HRSA guidance on the GPO exclusion (HRSA Release 2013-1); FDA mobile health guidance (FDA-2011-D-0530); andtrack and trace bills (S.957 &H.R.1919). | Centers For Medicare and Medicaid Services (CMS),Federal Emergency Management Agency (FEMA),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Housing & Urban Development, Dept of (HUD),Internal Revenue Service (IRS),SENATE,White House Office | 270000 | 0 | 0 | 2013-10-14T14:39:55.730000-04:00 | |
| 1442191 | DUTKO WORLDWIDE, LLC b25dcdd6-c226-41ff-9890-b8447f1e2e7d | 3T | DUTKO WORLDWIDE, LLC | 12868 | NEWAYS INTERNATIONAL | 2013 | third_quarter | PHA | Monitor legislation pertaining to dietary supplements and pharmaceuticals, particularly the Food Safety Modernization Act (PL 111-353) and Patient Protection and Affordable Care Act (PL 111-148). | Executive Office of the President (EOP),HOUSE OF REPRESENTATIVES,SENATE | 20000 | 0 | 1 | 2013-10-14T18:34:14.537000-04:00 | |
| 1442479 | RED+BLUE STRATEGIES 4e31cabe-ddf4-4799-858b-430382693ea7 | Q3 | RED+BLUE STRATEGIES | 400693064 | BLUE CROSS BLUE SHIELD OF MASSACHUSETTS | 2013 | third_quarter | PHA | H.R. 3204 - The Drug Quality and Security Act as it relates to safety of medications covered by BCBSMA Issues related to opioid abuse interventions and policies to help curb fraud and abuse, while at the same time improving outcomes for individuals with pain management needs. | Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE | 40000 | 0 | 0 | 2013-10-15T10:44:36.800000-04:00 | |
| 1442561 | ROCK & ASSOCIATES b85f9265-d81d-4734-880d-b35817d2897e | Q3 | ROCK & ASSOCIATES | 33545 | US COMPOUNDING | 2013 | third_quarter | PHA | S.959, H.R. 3089 & H.R. 3204 legislation affecting the operation of compounding pharmacies and the availability of compounded medications. | HOUSE OF REPRESENTATIVES,SENATE | 0 | 0 | 2013-10-15T11:41:18.690000-04:00 | ||
| 1443039 | ALZHEIMER'S FOUNDATION OF AMERICA 5b779a6b-5c9b-4a2e-a791-92fddc3ee355 | Q3 | ALZHEIMER'S FOUNDATION OF AMERICA | 323158 | ALZHEIMER'S FOUNDATION OF AMERICA | 2013 | third_quarter | PHA | CMS national coverage decision on PET imaging for AD diagnosis. | Administration on Aging,Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Office of Management & Budget (OMB),SENATE | 26000 | 0 | 0 | 2013-10-15T15:43:08.910000-04:00 | |
| 1443056 | CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. bdafac9a-fdfc-4a1a-bbaa-55e03724f9a9 | Q3 | CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. | 8511 | AMERICAN SOCIETY OF HEMATOLOGY | 2013 | third_quarter | PHA | Issues related to drug shortages. | Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE | 40000 | 0 | 0 | 2013-10-15T15:49:16.440000-04:00 | |
| 1443072 | CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. 3cbaa3cf-6d63-4f04-abe5-c3d678483d0e | Q3 | CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. | 8511 | THE HEMOPHILIA ALLIANCE | 2013 | third_quarter | PHA | Issues related to the 340B drug discount program. | Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,SENATE | 30000 | 0 | 0 | 2013-10-15T15:53:24.017000-04:00 | |
| 1443081 | CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. 609c813e-19ba-4b4f-b421-67fedd99518d | Q3 | CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. | 8511 | NATIONAL HEMOPHILIA FOUNDATION | 2013 | third_quarter | PHA | Issues related to hemophilia treatments, specialty pharmacies and the 340B drug purchasing program. HR 460 - Patients Access to Treatment Act | Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),Office of Management & Budget (OMB),SENATE | 50000 | 0 | 0 | 2013-10-15T15:55:30.330000-04:00 | |
| 1443101 | CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. 90066502-dc56-4fdb-a88a-79e5273adaf0 | Q3 | CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. | 8511 | NATIONAL ASSOCIATION OF EPILEPSY CENTERS | 2013 | third_quarter | PHA | Issues related to anti-epileptic drugs. | Agency for Healthcare Research & Quality (AHRQ),Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE | 10000 | 0 | 0 | 2013-10-15T15:58:41.567000-04:00 | |
| 1443224 | NOVO NORDISK INC. f675a849-dda3-41ab-a116-add67b24b2c1 | Q3 | NOVO NORDISK INC. | 284790 | NOVO NORDISK INC. | 2013 | third_quarter | PHA | H.R. 3204 Drug Quality and Security Act, H.R.1919 Safeguarding America's Pharmaceuticals Act of 2013 and S.959 Pharmaceutical Compounding Quality and Accountability Act (for track and trace supply chain provisions); issues regarding biosimilars; 340B | Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Executive Office of the President (EOP),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE,Veterans Affairs, Dept of (VA) | 500000 | 0 | 0 | 2013-10-15T16:29:26.333000-04:00 | |
| 1443581 | UNIVERSITY OF IOWA 889ca90c-f37f-416c-bc87-65c3f45d68c2 | Q3 | UNIVERSITY OF IOWA | 49191 | UNIVERSITY OF IOWA | 2013 | third_quarter | PHA | Increased appropriations for systems to shorten the time between development of a drug and its release to the public FDA reform as it relates to drug development and research Collaborative research on drug development Human factors research related to neuropharmaceuticals | Agriculture, Dept of (USDA),Centers For Medicare and Medicaid Services (CMS),Defense, Dept of (DOD),Federal Emergency Management Agency (FEMA),Health & Human Services, Dept of (HHS),Homeland Security, Dept of (DHS),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE,Transportation, Dept of (DOT) | 85562 | 0 | 0 | 2013-10-16T10:02:14.043000-04:00 | |
| 1443626 | HANCE SCARBOROUGH 46fb1942-c88a-4994-ae71-69ffabd4ba27 | Q3 | HANCE SCARBOROUGH | 17443 | ALLIANCE OF INDEPENDENT PHARMACISTS - TEXAS | 2013 | third_quarter | PHA | Federal legislation affecting the practice of pharmacy and FDA regulation of compounded drugs. | HOUSE OF REPRESENTATIVES,SENATE | 10000 | 0 | 0 | 2013-10-16T10:18:37.717000-04:00 | |
| 1443640 | HANCE SCARBOROUGH 05507985-9bb0-4946-b834-9db24eba6289 | Q3 | HANCE SCARBOROUGH | 17443 | INTRATHECAL CUSTODY ACCOUNT SUPPORTERS (INFORMAL COALITION) | 2013 | third_quarter | PHA | Monitored legislation related to physician control and patient access to intrathecal pump applications for patients with chronic pain. | HOUSE OF REPRESENTATIVES,SENATE | 10000 | 0 | 0 | 2013-10-16T10:22:44.637000-04:00 | |
| 1443814 | 340B HEALTH 8f8588a7-aad3-4d2f-94e6-4bd047459982 | Q3 | 340B HEALTH | 316434 | 340B HEALTH | 2013 | third_quarter | PHA | - The 340B Drug Discount program - Medicare Part B Drug Reimbursement, H.R. 2869 - Orphan Drug Rule, ACA implementation - SGR reform pay-fors | Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,SENATE | 231546 | 0 | 0 | 2013-10-16T11:09:13.290000-04:00 | |
| 1444006 | RED+BLUE STRATEGIES 7b034c38-e0f6-4ba2-bb56-c26b2fe8e24c | Q3 | RED+BLUE STRATEGIES | 400693064 | EXPRESS SCRIPTS INC. | 2013 | third_quarter | PHA | H.R. 1367 - FEHBP Prescription Drug Integrity, Transparency and Cost Savings Act - focused on policies that would negatively impact access to mail order pharmacy Rules, regulations and guidance specific to prescription drug pricing, generic utilization and specialty pharmacy.Issues impacting PBMs in up coming health related legislation. Policies related to stopping the diversion of prescription medications in the nation's drug supply chain. Changes in International Naming policies for generic medications. ACA-related regulations impacting new rules for Exchanges specific to the promulgation of the prescription drug benefits. H.R. 3204 - The Drug Quality and Security Act. Legislation to address secure the pharmaceutical supply chain and drug compounding practices. | Centers For Medicare and Medicaid Services (CMS),Executive Office of the President (EOP),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE | 60000 | 0 | 0 | 2013-10-16T12:11:58.917000-04:00 | |
| 1444058 | THE OB-C GROUP, LLC 30652916-03fc-4102-9d61-31a4963a1982 | Q3 | THE OB-C GROUP, LLC | 29802 | ELI LILLY | 2013 | third_quarter | PHA | No specific bill number: matters relating to pharmaceutical manufacturers including Medicare Part D. | HOUSE OF REPRESENTATIVES,SENATE | 20000 | 0 | 0 | 2013-10-16T12:23:25.370000-04:00 | |
| 1444203 | RED+BLUE STRATEGIES 51c89a96-4571-4cf0-9899-85d930296e4f | Q3 | RED+BLUE STRATEGIES | 400693064 | PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION (PCMA) | 2013 | third_quarter | PHA | H.R. 1367 - FEHBP Prescription Drug Integrity, Transparency and Cost Savings Act - focused on policies that would negative impact peoples access to prescription medications through mail. Issues related to the practice of giving coupons for certain prescription medications.Ongoing discussions in the Congress regarding track and trace policies to increase safety in the nation's prescription drug supply chain. CMS call letter focused on changes in policies regarding mail order and pharmacy networks. | Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE | 60000 | 0 | 0 | 2013-10-16T13:46:39.087000-04:00 | |
| 1444219 | INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP) 27135dba-a851-4565-a777-b6c3b514d5f9 | Q3 | INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP) | 400337570 | INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS (IACP) | 2013 | third_quarter | PHA | Legislation Related to Compounding Pharmacies and federal reform of the Food, Drug and Cosmetic Act related to compounding. S. 995, HR 3204 | Drug Enforcement Administration (DEA),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE | 187156 | 0 | 0 | 2013-10-16T13:54:47.117000-04:00 | |
| 1444230 | RED+BLUE STRATEGIES b84dbc4c-a7f0-4e19-81af-c93fcce8de24 | Q3 | RED+BLUE STRATEGIES | 400693064 | PEW CHARITABLE TRUSTS | 2013 | third_quarter | PHA | Issues related to continuing to increase the supply of new and innovative antibiotics that will help to treat the myriad antibiotic resistant strains of bugs like MRSA. H.R. 3204 - The Drug Quality and Security Act - Legislation to address the security of the nation's pharmaceutical supply chain anddrug compounding practices. H.R. 933 - Consolidation and Further Continuing Appropriations Act of 2013 - Focused on funding for the FDA, CDC and other public health related industries. | Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE | 30000 | 0 | 0 | 2013-10-16T13:57:52.667000-04:00 | |
| 1444421 | THEODOSIOU CONSULTANTS 57434c5c-5b66-49a6-bb07-e0633fb0a7b3 | Q3 | THEODOSIOU CONSULTANTS | 54621 | THEODOSIOU CONSULTANTS | 2013 | third_quarter | PHA | Pharmakentic Study | Administration for Children & Families (ACF),HOUSE OF REPRESENTATIVES,SENATE | 0 | 0 | 2013-10-16T14:56:01.180000-04:00 | ||
| 1444657 | BROWN RUDNICK LLP 9711f0b4-9591-4200-996a-8b57c2afd968 | 3A | BROWN RUDNICK LLP | 287895 | HOSPIRA, INC. | 2013 | third_quarter | PHA | -- Issues relating to generic drug labeling -- S. 959: The Pharmaceutical Quality, Security and Accountability Act -- H.R. 3204: The Compounding Clarity Act | HOUSE OF REPRESENTATIVES,SENATE,White House Office | 50000 | 0 | 0 | 2013-10-16T15:50:59.130000-04:00 | |
| 1444968 | AMERICA'S HEALTH INSURANCE PLANS, INC. (AHIP) 1704ddef-f7cf-4175-8d07-cafb4cc83bff | Q3 | AMERICA'S HEALTH INSURANCE PLANS, INC. (AHIP) | 1581 | AMERICA'S HEALTH INSURANCE PLANS INC (AHIP) | 2013 | third_quarter | PHA | H.R. 1367, FEHBP Prescription Drug Integrity, Transparency, and Cost Savings Act (Lynch) FEHBP prescription drugs16. Specific Lobbying Issues (continued): S. 214, Preserve Access to Affordable Generics Act (Klobuchar) access to generic drugs H.R. 3204, Drug Quality and Security Act (Upton) - safety of drug compounding and the security of the pharmaceutical supply chain Regulatory Issues: Issues relating to long term safety and effectiveness of medical devices and drugs, including registries; issues relating to post-market surveillance of drugs and medical devices; issues relating to access for investigational drugs; and other issues relating to health care reform implementation. | Agency for Healthcare Research & Quality (AHRQ),Centers For Medicare and Medicaid Services (CMS),Executive Office of the President (EOP),Federal Bureau of Investigation (FBI),Federal Trade Commission (FTC),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Internal Revenue Service (IRS),Justice, Dept of (DOJ),Labor, Dept of (DOL),Medicare Payment Advisory Commission (MedPAC),Office of Management & Budget (OMB),Office of Personnel Management (OPM),Pension & Welfare Benefits Administration,SENATE,Treasury, Dept of,White House Office | 2210000 | 0 | 0 | 2013-10-16T17:29:16.553000-04:00 | |
| 1445060 | CAPITOL HILL CONSULTING GROUP e3db9308-2373-458d-a6ac-6991d26d74ba | Q3 | CAPITOL HILL CONSULTING GROUP | 72053 | PURDUE PHARMA LLP | 2013 | third_quarter | PHA | Controlled Drug Substances Act (21 USC 13) Stop Tampering of Prescription Pills Act of 2013 (H.R. 486) | HOUSE OF REPRESENTATIVES,SENATE | 35000 | 0 | 0 | 2013-10-16T17:48:51.087000-04:00 | |
| 1445167 | KNIGHT CAPITOL CONSULTANTS 3b3d64e7-7e64-40cc-afcd-e78794345f22 | Q3 | KNIGHT CAPITOL CONSULTANTS | 40036301 | GENZYME CORPORATION | 2013 | third_quarter | PHA | Adequate funding for programs of the Food and Drug Administration, including implementation of the Prescription Drug User Fee Act (FY 2014 appropriations for the FDA, H.R. 2410/S. 1244/H.J. Res. 59). Assess potential impact of sequestration on public health/food and drug programs (FY 2014 appropriations for HHS, S. 1284). | HOUSE OF REPRESENTATIVES,SENATE | 40000 | 0 | 0 | 2013-10-16T19:33:34.300000-04:00 | |
| 1445608 | BROWN RUDNICK LLP 9b0ad315-012d-4fb3-917d-52f2157a3ba4 | Q3 | BROWN RUDNICK LLP | 287895 | HEALTHCARE DISTRIBUTION ALLIANCE F/K/A HEALTHCARE DISTRIBUTION MANAGEMENT ASSOC | 2013 | third_quarter | PHA | -- S. 621 and HR 1285: Safe Prescribing Act of 2013; -- H.R. 1919: Safeguarding America's Pharmaceuticals Act of 2013; -- H.R. 3204: The Drug Quality and Safety Act; -- S. 957: The Drug Supply Chain Security Act; -- S. 1277: Combating Prescription Drug Abuse Act | HOUSE OF REPRESENTATIVES,SENATE | 50000 | 0 | 0 | 2013-10-17T09:23:23.773000-04:00 | |
| 1446015 | ST SHARED SERVICES LLC DBA KEENOVA THERAPEUTICS (FKA ST SHARED SERVICES LLC DBA MNK PHARMACEUTICALS) e75daeed-b95a-412c-b15c-40004f7eba20 | Q3 | ST SHARED SERVICES LLC DBA KEENOVA THERAPEUTICS (FKA ST SHARED SERVICES LLC DBA MNK PHARMACEUTICALS) | 401095056 | ST SHARED SERVICES LLC DBA KEENOVA THERAPEUTICS (FKA ST SHARED SERVICES LLC DBA | 2013 | third_quarter | PHA | Drug pedigree and compounding | Energy, Dept of,HOUSE OF REPRESENTATIVES,SENATE | 160000 | 0 | 0 | 2013-10-17T10:59:08.663000-04:00 | |
| 1446325 | THE MATHIS HARPLE GROUP cd248053-b812-4cee-b817-34ffc3c32df3 | Q3 | THE MATHIS HARPLE GROUP | 322911 | PILMA | 2013 | third_quarter | PHA | Medicare Pt D Rebates; TransPacific Partnership | HOUSE OF REPRESENTATIVES,SENATE | 20000 | 0 | 0 | 2013-10-17T11:56:22.067000-04:00 | |
| 1446337 | AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS 197aaf38-cfac-4551-b2ea-6d7fc798a2e4 | Q3 | AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS | 3457 | AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS | 2013 | third_quarter | PHA | Contact concerning FDA authority to manage drug shortages and regulation of pharmacy compounding. Contact concerning HRSA oversight of 340B drug discount program. Communication with the FDA on the REMS program. Contact concerning S. 959, Pharmaceutical Compounding and Quality Accountability Act, (all sections) to address FDA oversight of certain drug compounding entities. Contact concerning HR 3204 (all sections) the Drug Quality and Security Act. | Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,SENATE | 250000 | 0 | 0 | 2013-10-17T11:57:25.207000-04:00 | |
| 1446955 | CONSUMER HEALTHCARE PRODUCTS ASSOCIATION d2a6ee41-4e40-4b98-97aa-13c8a2c74e55 | Q3 | CONSUMER HEALTHCARE PRODUCTS ASSOCIATION | 29403 | CONSUMER HEALTHCARE PRODUCTS ASSOCIATION | 2013 | third_quarter | PHA | PseudoephedrinePseudoephedrine - potential legislation to implement real-time, stop-sale electronic tracking system for sales of medications containing pseudoephedrine in order to preserve consumer access to the ingredient, common in popular cold and allergy medications (no bill number) and oppose prescription requirement (no bill number). | Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,Office of Natl Drug Control Policy (NDCP),SENATE | 280000 | 0 | 0 | 2013-10-17T13:54:35.443000-04:00 | |
| 1447122 | EXPRESS SCRIPTS, INC. ae9dc024-53c6-4fc3-896f-a50abb43567c | Q3 | EXPRESS SCRIPTS, INC. | 294416 | EXPRESS SCRIPTS, INC. | 2013 | third_quarter | PHA | Policies related to the Federal Employees Health Benefit Program's pharmacy benefit (HR 1367); Regulatory design and coverage of pharmacy benefits in health reform Exchanges and the commercial market (EHB, grandfathering, Rx quality, eRx, PBM disclosure requirements, MLR); regulatory implementation of a pathway for the approval of biosimilars; REMs; 340b program; policies placing restrictions on pharmacy benefit designissues regarding making prescription drugs more affordable (generic user fees; pedigree; pathway for biosimilars; REMs). General issues dealing with prescription drug abuse including Medicare Lock-in programs. General issues dealing with regulating pharmacy drug compounding. S. 867, the Medicare Prescription Drug Program Integrity and Transparency Act. | Centers For Medicare and Medicaid Services (CMS),Congressional Budget Office (CBO),Executive Office of the President (EOP),Federal Trade Commission (FTC),Food & Drug Administration (FDA),Government Accountability Office (GAO),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Internal Revenue Service (IRS),Labor, Dept of (DOL),Medicare Payment Advisory Commission (MedPAC),Office of Personnel Management (OPM),SENATE,White House Office | 670000 | 0 | 0 | 2013-10-17T14:22:53.787000-04:00 | |
| 1447199 | BUCHANAN INGERSOLL & ROONEY PC 5f25aeb7-6a32-4a8d-b9d1-8f7044846d72 | Q3 | BUCHANAN INGERSOLL & ROONEY PC | 55291 | GENERIC ANIMAL DRUG ALLIANCE | 2013 | third_quarter | PHA | Legislative issues relating to United States Food & Drug Administration. | Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE | 10000 | 0 | 0 | 2013-10-17T14:32:28.037000-04:00 | |
| 1447275 | BUCHANAN INGERSOLL & ROONEY PC 4329a685-94e2-450c-a78a-324429c48871 | Q3 | BUCHANAN INGERSOLL & ROONEY PC | 55291 | PENNSYLVANIA BIOTECHNOLOGY ASSOCIATION - ALA: PENNSYLVANIA BIO | 2013 | third_quarter | PHA | Life sciences, orphan drugs, medical devices, budget, PDUFA | HOUSE OF REPRESENTATIVES,SENATE | 0 | 0 | 2013-10-17T14:42:11.210000-04:00 | ||
| 1447641 | MAYNARD NEXSEN PC c6f7b338-80fb-48bd-9748-9f4cf9bd4472 | Q3 | MAYNARD NEXSEN PC | 60116 | TOTAL PAIN SOLUTIONS, LLC | 2013 | third_quarter | PHA | HR 3089 - Compounding Clarity Act of 2013 Department of Defense (TriCare) = worked with Tricare on proposed prescription drug reimbursement change. | HOUSE OF REPRESENTATIVES,SENATE | 30000 | 0 | 0 | 2013-10-17T15:17:00.347000-04:00 | |
| 1448125 | BLUECROSS BLUESHIELD OF TENNESSEE 1dbad83c-6ae4-4571-a7d8-31754f8a31a8 | Q3 | BLUECROSS BLUESHIELD OF TENNESSEE | 6440 | BLUECROSS BLUESHIELD OF TENNESSEE | 2013 | third_quarter | PHA | General Pharmacy Issues The Pharmaceutical Quality, Security, and Accountability Act S.959 | HOUSE OF REPRESENTATIVES,SENATE | 40000 | 0 | 0 | 2013-10-17T16:06:24.613000-04:00 | |
| 1449013 | EMPIRE CONSULTING GROUP 1abd701c-86f3-462e-a30f-1e7bdfd2b188 | Q3 | EMPIRE CONSULTING GROUP | 400703105 | PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA | 2013 | third_quarter | PHA | Issues relating to the Medicare Prescription Drug Act; issues relating to implementation of the Affordable Care Act; H.R. 1588, "Medicare Drug Savings Act of 2013"; 340 B Drug Discount Program; HR 3204, Drug Quality & Security Act | HOUSE OF REPRESENTATIVES | 40000 | 0 | 0 | 2013-10-17T18:25:45.463000-04:00 | |
| 1449180 | THE INGRAM GROUP LLC 5c240d4c-811d-45f7-bda4-f1a4ca20350c | Q3 | THE INGRAM GROUP LLC | 400577737 | PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA (PHRMA) | 2013 | third_quarter | PHA | Issues related to pharmaceutical importation, issues related to generic drugs, and S.CON.RES.8, An original concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2014, revising the appropriate budgetary levels for fiscal year 2013, and setting forth the appropriate budgetary levels for fiscal years 2015 through 2023. Issues related to the Drug Supply Chain Security Act of 2013 S.957. | HOUSE OF REPRESENTATIVES,SENATE | 60000 | 0 | 0 | 2013-10-17T21:24:59.617000-04:00 | |
| 1449756 | HEALTHCARE DISTRIBUTION ALLIANCE(HDA)(FORMERLY HEALTHCARE DISTRIBUTION MANAGEMENT ASSOCIATION (HDMA) ee1c2c7b-8dd6-4b1e-b3b2-cc2bc7136805 | Q3 | HEALTHCARE DISTRIBUTION ALLIANCE(HDA)(FORMERLY HEALTHCARE DISTRIBUTION MANAGEMENT ASSOCIATION (HDMA) | 28776 | HEALTHCARE DISTRIBUTION ALLIANCE (FORMERLY - HDMA) | 2013 | third_quarter | PHA | Rx Pedigree (S. 959, S. 957, H.R. 1919) (H.R. 2186) (H.R. 3204); Prescription Drug Monitoring Programs; Drug Abuse (S. 348), Hydrocodone Rescheduling (H.R. 1285, S. 621); Dextromethorphan (S. 644), Prescription Drug Abuse (S. 1277); Drug Shortages - Gray Market (H.R. 1958); Counterfeit Drugs; Importation of Prescription Drugs | Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE | 285000 | 0 | 0 | 2013-10-18T09:48:00.877000-04:00 | |
| 1449809 | SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING 0636918b-f317-4c69-ab36-a279d1ef8a38 | Q3 | SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 35968 | SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2013 | third_quarter | PHA | Pharmacy compounding of radiopharmaceuticals; The Drug Quality and Security Act (H.R. 3204). | Centers For Medicare and Medicaid Services (CMS),Energy, Dept of,Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE | 80000 | 0 | 0 | 2013-10-18T10:00:17.547000-04:00 | |
| 1450398 | AMERICAN ASSOCIATION OF NURSE PRACTITIONERS 434d2e97-368f-494c-a67e-f371a0d2f7cd | Q3 | AMERICAN ASSOCIATION OF NURSE PRACTITIONERS | 401040928 | AMERICAN ASSOCIATION OF NURSE PRACTITIONERS | 2013 | third_quarter | PHA | Legislation and policies relating to: FDA Drug Safety and Risk Management Advisory Committee January 25 recommendation to reschedule hydrocodone as a Schedule II controlled substance H.R. 1285 - To amend the Controlled Substances Act to make any substance containing hydrocodone a schedule II drugH.R. 1919 - Safeguarding America's Pharmaceuticals Act S. 621 Safe Prescribing Act S. 959 Pharmaceutical Compounding Quality and Accountability Act H.R. 3089 Compounding Clarity Act H.R. 3204 Drug Quality and Security Act | Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Medicare Payment Advisory Commission (MedPAC),Office of Management & Budget (OMB),SENATE,White House Office | 84089 | 0 | 0 | 2013-10-18T11:25:44.733000-04:00 | |
| 1450517 | WHITMER & WORRALL, LLC 154e2a8c-ed8a-48ba-90be-75bc3f494465 | Q3 | WHITMER & WORRALL, LLC | 292892 | PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA (PHRMA) | 2013 | third_quarter | PHA | Issues related to monitoring healthcare reform. | Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,State, Dept of (DOS) | 30000 | 0 | 0 | 2013-10-18T11:34:32.613000-04:00 | |
| 1450763 | AMERICAN OPTOMETRIC ASSOCIATION 495f701b-5bc0-4fdc-82b3-34bf579c7807 | Q3 | AMERICAN OPTOMETRIC ASSOCIATION | 2981 | AMERICAN OPTOMETRIC ASSOCIATION | 2013 | third_quarter | PHA | HR 1285, To amend the Controlled Substances Act to make any substance containing hydrocodone a schedule II drug, all sections relating to vision. S 621, Safe Prescribing Act of 2013, all sections relating to vision. | HOUSE OF REPRESENTATIVES,SENATE | 280000 | 0 | 0 | 2013-10-18T11:54:13.927000-04:00 | |
| 1451177 | EVERGREEN ASSOCIATES, LTD. 4152e43a-7e49-44a2-843f-d5946007b0ad | Q3 | EVERGREEN ASSOCIATES, LTD. | 13984 | PHARMACEUTICAL PRINTED LITERATURE ASSOCIATION | 2013 | third_quarter | PHA | - RIN: 0910-AG18, Electronic Distribution of Content Labeling for Human Prescription Drug and Biological Products - Risk Communications: Consumer Medication Information, Medication Guides, Patient Package Inserts, Professional Inserts - P.L. 112-144: Food and Drug Administration Safety and Innovation Act: Title XI- Other Provisions, Subtitle C- Miscellaneous Provisions, Sec. 1140- Study on Drug Labeling by Electronic Means- HR 1919: Safeguarding Americas Pharmaceuticals Act of 2013: Section 8- Electronic labeling - S 957: Drug Supply Chain Security Act - S 959: Pharmaceutical Compounding and Accountability Act - H.R. 3204: Drug Quality and Security Act | Food & Drug Administration (FDA),Government Accountability Office (GAO),HOUSE OF REPRESENTATIVES,Office of Management & Budget (OMB),SENATE | 10000 | 0 | 0 | 2013-10-18T12:28:58.580000-04:00 | |
| 1451867 | BLUE CROSS AND BLUE SHIELD OF FLORIDA, INC. fbdc147d-f5f6-41d5-a040-bfe860baa432 | Q3 | BLUE CROSS AND BLUE SHIELD OF FLORIDA, INC. | 6382 | BLUE CROSS AND BLUE SHIELD OF FLORIDA INC | 2013 | third_quarter | PHA | No pharmacy lobbying activity reported during the 3rd quarter. | HOUSE OF REPRESENTATIVES,SENATE | 490000 | 0 | 0 | 2013-10-18T13:30:19.063000-04:00 | |
| 1451891 | NATIONAL PATIENT ADVOCATE FOUNDATION 934bd007-27ce-4631-ac50-94a5c52fc59b | Q3 | NATIONAL PATIENT ADVOCATE FOUNDATION | 28311 | NATIONAL PATIENT ADVOCATE FOUNDATION | 2013 | third_quarter | PHA | Specialty Tiers | Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE | 36807 | 0 | 0 | 2013-10-18T13:33:27.580000-04:00 | |
| 1452129 | CROSSROADS STRATEGIES, LLC 9f09fdba-6c2c-4529-93f7-2ee47a3d28a9 | Q3 | CROSSROADS STRATEGIES, LLC | 400531586 | LUMARA HEALTH | 2013 | third_quarter | PHA | S.959, Pharmaceutical Quality, Security, and Accountability Act; H.R.1919, Safeguarding America's Pharmaceuticals Act of 2013; H.R.3089, Compounding Clarity Act of 2013; FDA related issues-specifically pharmacy compounding. | HOUSE OF REPRESENTATIVES,SENATE | 50000 | 0 | 0 | 2013-10-18T14:01:00.907000-04:00 | |
| 1452136 | ARNOLD & PORTER KAYE SCHOLER LLP ba9d7c6f-5739-48a0-b816-0213f9073cd5 | Q3 | ARNOLD & PORTER KAYE SCHOLER LLP | 4301 | INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS | 2013 | third_quarter | PHA | Issues related to the regulation of the practice of pharmacy compounding. | HOUSE OF REPRESENTATIVES,SENATE | 60000 | 0 | 0 | 2013-10-18T14:03:05.843000-04:00 | |
| 1452422 | VORYS ADVISORS, LLC f3784435-856b-4091-ab17-d30b8fe50080 | Q3 | VORYS ADVISORS, LLC | 400873558 | AMERISOURCEBERGEN CORPORATION | 2013 | third_quarter | PHA | Various health care proposals | HOUSE OF REPRESENTATIVES,SENATE | 0 | 0 | 2013-10-18T14:25:01.047000-04:00 | ||
| 1452666 | AMERICAN VETERINARY MEDICAL ASSOCIATION 08c75b06-c435-4514-8acb-e836b8937cd6 | Q3 | AMERICAN VETERINARY MEDICAL ASSOCIATION | 3630 | AMERICAN VETERINARY MEDICAL ASSOCIATION | 2013 | third_quarter | PHA | H.R. 1150 Preservation of Antibiotics for Medical Treatment Act; S. 959 Pharmaceutical Quality, Security, and Accountability Act S. 959 Pharmaceutical Quality, Security, and Accountability Act; S.622 Animal Drug and Animal Generic Drug user Fee Act H.R. 1407 Animal Drug User Fee Act; H.R. 1408 Animal Generic Drug User Fee Act; H.R. 1528/S. 1171 Veterinary Medicine Mobility Act; Fairness to Pet owners Act/Veterinary Prescription writingPHA/AGR - discussions with Congressional staff about DEA regulations impending practice of veterinary medicine; seeking passage of legislation to change underlying statute (HR 1582/S 1171) PHA - discussions with Congressional staff expressing the need for compounding of medications for use in animals PHA - inquiries to and discussions with Congressional staff and Federal Trade Commission on veterinary pet prescriptions | Agriculture, Dept of (USDA),Bureau of Labor Statistics (BLS),Commerce, Dept of (DOC),Defense, Dept of (DOD),Environmental Protection Agency (EPA),Federal Trade Commission (FTC),Government Accountability Office (GAO),Health & Human Services, Dept of (HHS),Homeland Security, Dept of (DHS),HOUSE OF REPRESENTATIVES,Office of Management & Budget (OMB),SENATE | 140000 | 0 | 0 | 2013-10-18T14:41:48.767000-04:00 | |
| 1452740 | THE DUBERSTEIN GROUP INC. 71f42eef-3ba5-418c-9121-6e02f5cf824e | Q3 | THE DUBERSTEIN GROUP INC. | 12675 | PFIZER INC. | 2013 | third_quarter | PHA | Pharmaceutical issues, including track and trace legislation - HR 1919, Safeguarding America's Pharmaceuticals Act of 2013; S 957, Drug Supply Chain Security Act; HR 3204, Drug Quality and Security Act. Specialty drug tiers - HR 460, Patients' Access to Treatments Act of 2013.Regulation of compounded drugs - HR 3019, S.A.F.E. Compounded Drugs Act of 2013; S 959, Pharmaceutical Quality, Security, and Accountability Act; HR 3204, Drug Quality and Security Act. | HOUSE OF REPRESENTATIVES,SENATE | 100000 | 0 | 0 | 2013-10-18T14:44:23.327000-04:00 | |
| 1452748 | THE DUBERSTEIN GROUP INC. 1f302404-012c-4ffd-b499-e947b0fe6794 | Q3 | THE DUBERSTEIN GROUP INC. | 12675 | PHRMA INC. | 2013 | third_quarter | PHA | Pharmaceutical issues, including Track and Trace - HR 1919, Safeguarding America's Pharmaceuticals Act of 2013; HR 3204, Drug Quality and Security Act; S 957, Drug Supply Chain Security Act. | HOUSE OF REPRESENTATIVES | 100000 | 0 | 0 | 2013-10-18T14:45:26.610000-04:00 | |
| 1452845 | PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION 3ed6c5b9-482e-417f-85c5-49b61853a3aa | Q3 | PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION | 31348 | PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION | 2013 | third_quarter | PHA | Provisions of PL 111-148 and PL 111-152 impacting Medicare Part D such as formulary requirements, PBM disclosure provisions, closing the Part D coverage gap Regulatory design and coverage of pharmacy benefits in health reform exchanges and the commercial market (essential health benefits, grandfathering, value-based insurance design, e-prescribing, PBM disclosure requirements, and medical loss ratio).Regulatory and proposed legislative changes to Medicare part D including pharmacy networks, classes of clinical concern, mail-service pharmacy, EGWP waivers, MTM expansion, long term care short-term fills, recovery audit contractors. Implementation of changes to the definition of Average Manufacturer Price in Medicaid Issues related to the management of Medicaid prescription drug benefits Legislation to promote generic drugs. Regulatory Implementation of the HITECH Act. FDA issues related to the Prescription Drug User Fee Act (PDUFA) (generic user fees, pedigree, REMs); implementation of approval pathway for generic biologic drugs, 340B program. Issues related to the compounding of certain drugs. S. 77, Prescription Drug and Health Improvement Act S. 557, Medication Therapy Management Empowerment Act H.R. 460, Patients Access to Treatments Act H.R. 1188, Preserving Our Hometown Independent Pharmacies Act H.R. 1367, FEHBP Prescription Drug Integrity, Transparency, and Cost Savings Act H.R. 1024, Medication Therapy Management Empowerment Act S.867, Medicare Prescription Drug Program Integrity and Transparency Act H.R. 2960, Medicare Prescription Drug Integrity Act of 2013 | Centers For Medicare and Medicaid Services (CMS),Executive Office of the President (EOP),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Labor, Dept of (DOL),SENATE | 567911 | 0 | 0 | 2013-10-18T14:53:15.173000-04:00 | |
| 1452881 | CAPITOLOGIC LLC af5fce7e-c0d8-4156-86f0-9e63174c6881 | 3T | CAPITOLOGIC LLC | 400426045 | BULALAW, LLC | 2013 | third_quarter | PHA | Federal funding of illegal prescription drug market interventions | Drug Enforcement Administration (DEA),HOUSE OF REPRESENTATIVES,Justice, Dept of (DOJ),Natl Institute of Justice,Office of Justice Program,SENATE | 0 | 1 | 2013-10-18T14:55:27.437000-04:00 | ||
| 1452985 | THE PROCTER AND GAMBLE COMPANY 715fef79-c06e-4c1b-a60b-8d0463bf993d | Q3 | THE PROCTER AND GAMBLE COMPANY | 32225 | THE PROCTER AND GAMBLE COMPANY | 2013 | third_quarter | PHA | Dextromethorphan Abuse Reduction; Regulation of OTC drugs, devices and cosmetics; S.644, Preventing Abuse of Cough Treatments Act of 2013 | Bureau of Citizenship & Immigration Services (BCIS),Commerce, Dept of (DOC),Commodity Futures Trading Commission (CFTC),Consumer Product Safety Commission (CPSC),Energy, Dept of,Environmental Protection Agency (EPA),Executive Office of the President (EOP),Federal Communications Commission (FCC),Federal Trade Commission (FTC),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Homeland Security, Dept of (DHS),HOUSE OF REPRESENTATIVES,Intl Trade Administration (ITA),Justice, Dept of (DOJ),Natl Security Council (NSC),Office of Science & Technology Policy (OSTP),Patent & Trademark Office (PTO),Securities & Exchange Commission (SEC),SENATE,State, Dept of (DOS),Transportation, Dept of (DOT),Treasury, Dept of,U.S. Agency for International Development (USAID),U.S. Customs & Border Protection,U.S. Immigration & Customs Enforcement (ICE),U.S. International Trade Commission (ITC),U.S. Trade Representative (USTR) | 759481 | 0 | 0 | 2013-10-18T15:03:29.533000-04:00 | |
| 1453318 | AMERICAN PHARMACISTS ASSOCIATION 2fd977fe-18a7-45e2-b20d-a0d0f4215db6 | Q3 | AMERICAN PHARMACISTS ASSOCIATION | 3071 | AMERICAN PHARMACISTS ASSOCIATION | 2013 | third_quarter | PHA | HCR(PL 111-152/111-148); Medicare Part D; Medication Therapy Management; Medicare Part B; reimbursement for pharmacist services; Social Security Act; DME; CMMI; transitions of care; risk evaluation and mitigation services; prescription drug monitoring program; prescription drug abuse; hydrocodone; opiods; track and trace/supply chain; ACOs; immunization; HIT; compounding; Sustainable Growth Rate; FDASIA(PL 112-144); tele-medicine; Medicare fraud, waste and abuse | Centers For Medicare and Medicaid Services (CMS),Drug Enforcement Administration (DEA),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,SENATE | 0 | 0 | 2013-10-18T15:20:27.280000-04:00 | ||
| 1453376 | KAISER FOUNDATION HEALTH PLAN INC. d53a18d2-a811-42a0-9a38-bbe835395e01 | Q3 | KAISER FOUNDATION HEALTH PLAN INC. | 21027 | KAISER FOUNDATION HEALTH PLAN INC | 2013 | third_quarter | PHA | S 3187 - Food and Drug Administration Safety and Innovation Act: A bill to amend the Federal Food, Drug and Cosmetic Act to revise and extend the user-fee programs for prescription drugs and medical devices, to establish user-fee programs for generic drugs and biosimilars, and for other purposes. Sponsor: Harkin (IA) | Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE | 110000 | 0 | 0 | 2013-10-18T15:22:49.187000-04:00 | |
| 1453543 | BROWN RUDNICK LLP 035f33ba-55f6-4c15-bf03-4aa8b2de44c1 | Q3 | BROWN RUDNICK LLP | 287895 | APOTEX CORPORATION | 2013 | third_quarter | PHA | H.R. 3204: The Drug Quality and Safety Act S. 959: The Pharmaceutical Quality, Security and Accountability Act | HOUSE OF REPRESENTATIVES,SENATE | 40000 | 0 | 0 | 2013-10-18T15:35:48.717000-04:00 | |
| 1453591 | BAKER DONELSON BEARMAN CALDWELL & BERKOWITZ 873fb0a6-6d25-4428-9386-360ab06ac858 | Q3 | BAKER DONELSON BEARMAN CALDWELL & BERKOWITZ | 5153 | AMERISOURCEBERGEN | 2013 | third_quarter | PHA | H.R. 1919/S. 957, Drug Supply Chain Security Act | HOUSE OF REPRESENTATIVES,SENATE | 50000 | 0 | 0 | 2013-10-18T15:41:07.687000-04:00 | |
| 1453600 | BROWN RUDNICK LLP 542d0db4-9fbb-4010-860d-490ebeca1092 | Q3 | BROWN RUDNICK LLP | 287895 | PRIME THERAPEUTICS | 2013 | third_quarter | PHA | HR 460: Patients' Access to Treatments Act of 2013 | Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE | 20000 | 0 | 0 | 2013-10-18T15:43:12.483000-04:00 | |
| 1454079 | MASON CONSULTING, LLC 59b5d778-4c09-463a-a035-2ff51904b428 | Q3 | MASON CONSULTING, LLC | 400660986 | AMERICAN ASSOCIATION OF NURSE PRACTITIONERS | 2013 | third_quarter | PHA | Legislation and policies relating to: FDA Drug Safety and Risk Management Advisory Committee recommendation to reschedule hydrocodone as a Schedule II controlled substance H.R. 1285 - To amend the Controlled Substances Act to make any substance containing hydrocodone a schedule II drug H.R. 1919 - Safeguarding America's Pharmaceuticals Act S. 621 - Safe Prescribing Act S. 959 - Pharmaceutical Compounding Quality and Accountability Act H.R. 3089 - Compounding Clarity Act H.R. 3204 - Drug Quality and Security Act | Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Medicare Payment Advisory Commission (MedPAC),Office of Management & Budget (OMB),SENATE,White House Office | 23450 | 0 | 0 | 2013-10-18T16:18:40.420000-04:00 | |
| 1454093 | MASON CONSULTING, LLC e33148e9-301d-4d52-8d42-55eb95a01884 | Q3 | MASON CONSULTING, LLC | 400660986 | NATIONAL ASSOCIATION OF PEDIATRIC NURSE PRACTITIONERS | 2013 | third_quarter | PHA | Legislation and policies relating to: FDA Drug Safety and Risk Management Advisory Committee January 25 recommendation to reschedule hydrocodone as a Schedule II controlled substance H.R. 1285 - To amend the Controlled Substances Act to make any substance containing hydrocodone a schedule II drug H.R. 1919 - Safeguarding Americas Pharmaceuticals Act S. 621 - Safe Prescribing Act S. 959 - Pharmaceutical Compounding Quality and Accountability Act H.R. 3089 - Compounding Clarity Act H.R. 3204 - Drug Quality and Security Act | Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Medicare Payment Advisory Commission (MedPAC),Office of Management & Budget (OMB),SENATE,White House Office | 23450 | 0 | 0 | 2013-10-18T16:21:43.280000-04:00 | |
| 1454151 | FOOD MARKETPLACE INC. 303be812-5d0a-4595-bdad-0442aa55c860 | Q3 | FOOD MARKETPLACE INC. | 15097 | FOOD MARKETPLACE INC | 2013 | third_quarter | PHA | S. 644 - Preventing Abuse of Cough Treatments Act of 2013 H.R. 2835 - Restoring Access to Medication ActS.622, H.R. 1407, H.R. 1408, the Animal Drug and Animal Generic Drug User Fee Reauthorization Act of 2013 H.R.1150, S. 1256: Preservation of Antibiotics for Medical Treatment Act of 2013 H.R. 1919 Safeguarding America's Pharmaceuticals Act of 2013 S.959: Pharmaceutical Compounding Quality and Accountability Act The Compounding Clarity Act | Agriculture, Dept of (USDA),Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,Labor, Dept of (DOL),Office of Management & Budget (OMB),SENATE | 125000 | 0 | 0 | 2013-10-18T16:26:01.217000-04:00 |
Advanced export
JSON shape: default, array, newline-delimited, object
CREATE TABLE lobbying_activities (
id INTEGER PRIMARY KEY,
filing_uuid TEXT NOT NULL,
filing_type TEXT NOT NULL,
registrant_name TEXT NOT NULL,
registrant_id INTEGER,
client_name TEXT NOT NULL,
filing_year INTEGER NOT NULL,
filing_period TEXT NOT NULL,
issue_code TEXT,
specific_issues TEXT,
government_entities TEXT,
income_amount INTEGER,
expense_amount INTEGER,
is_no_activity INTEGER DEFAULT 0,
is_termination INTEGER DEFAULT 0,
received_date TEXT,
CONSTRAINT fk_activity_filing FOREIGN KEY (filing_uuid)
REFERENCES lobbying_filings_raw(filing_uuid)
);
CREATE INDEX idx_act_client_name ON lobbying_activities(client_name COLLATE NOCASE);
CREATE INDEX idx_act_issue_code ON lobbying_activities(issue_code);
CREATE INDEX idx_act_filing_year ON lobbying_activities(filing_year);
CREATE INDEX idx_act_filing_uuid ON lobbying_activities(filing_uuid);